文献速递临床试验与 GCP基础与转化研究

基于高级影像引导的发病时间未知卒中静脉阿替普酶治疗:个体患者数据的系统综述与荟萃分析

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
PubMed 文献 · Lancet · 2020-11-08

本研究对发病时间未知且存在可挽救组织的卒中患者,系统检索并纳入4项随机试验的843例个体数据,比较静脉阿替普酶与安慰剂或标准治疗。

要点

  • 发病时间未知但DWI-FLAIR或灌注错配的卒中患者,阿替普酶可改善90天功能结局。
  • 阿替普酶组症状性颅内出血发生率高于对照组(3% vs <1%)。
  • 尽管死亡增加,严重残疾或死亡复合终点在阿替普酶组数值更低。

核心结论

  • 在发病时间未知且存在DWI-FLAIR或灌注错配的卒中患者中,静脉阿替普酶较安慰剂或标准治疗改善90天功能结局。
  • 尽管症状性颅内出血风险增加,所有功能结局均显示净获益,且严重残疾或死亡病例更少。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,检索2020年9月21日前发表的随机试验。
  • 纳入4项试验(WAKE-UP、EXTEND、THAWS、ECASS-4),共843例患者,阿替普酶组429例(51%),对照组414例(49%)。
  • 纳入标准为成人发病时间未知卒中,且灌注-弥散MRI、灌注CT或DWI-FLAIR错配。
  • 主要结局为90天mRS 0-1分,采用非条件混合效应逻辑回归估计治疗效应。

临床怎么用

  • 对发病时间未知但高级影像提示可挽救组织的卒中患者,可考虑静脉阿替普酶治疗以改善功能结局。
  • 治疗决策需权衡功能获益与症状性颅内出血及死亡风险增加。

局限性

  • 仅纳入4项随机试验的个体数据,样本量有限。
  • 各试验影像选择标准(DWI-FLAIR错配或灌注错配)存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. METHODS: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0-2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. FINDINGS: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10-2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05-1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06-2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4-6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52-1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03-4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22-25·50]; p=0·024). INTERPRETATION: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet. 2020. PMID: 33176180. doi:10.1016/S0140-6736(20)32163-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。